Skip to main content

Fiscal Wizard · Single-issue tearsheet

GYRE / Jun 20, 2026 Run #7171

GYRE

Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Composite verdict

F 26.8 / 100
Bearish setup · Trend Following 12 drivers · 3 gates blocking
  • Parabolic SAR Flip
  • Elder Force Index
  • Pin Bar
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 195th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 20 signals100% Bear
Momentum Bearish 3Mean-reversion Neutral 48
  • Late-stage trendTrend signals have been live for 65 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes fromMargin of safety -84%
Asset value $1.09Earnings power value $1.28Price $6.25

Priced above its no-growth earnings power value ($1.28/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

53.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Asset Turnover 100
Margin of Safety 0
Return on Assets 84
Forward P/E 0
Return on Capital Employed 83
OCF to Net Income 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Parabolic SAR Flip, Elder Force Index, Pin Bar); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Elder Force Index 9
Parabolic SAR Flip 9
Pin Bar 18

Risk Gates

3 blocking 7 caution

3 guards active, 19 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for GYRE.